Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

32.66 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
31 32 Next >
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
These two biotechs have a lot in common, but one is much better capitalized. 
Via The Motley Fool
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Where Will CRISPR Therapeutics Be in 5 Years?
The company hasn't performed well in the past five years, but things could change. 
Via The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Good medicines aren't always good business. 
Via The Motley Fool
2 Top Trends to Invest $500 In Right Now
Early investors in these trends may reap the rewards over time. 
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
You can get in early on these potential winners. 
Via The Motley Fool
Looking for Growth? These Companies' Revenue May Skyrocket
Catalysts on the horizon could drive gains in these top stocks. 
Via The Motley Fool
If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today
The returns are impressive, but will they continue to be so? 
Via The Motley Fool
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
They're both liable to grow by a lot, but one of them is a safer bet in the near term. 
Via The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
3 Top Healthcare Stocks Defying the Bear Market
Revenue at all three companies improved last quarter, and their share prices have followed suit. 
Via The Motley Fool
Better Bull Market Buy: CRISPR vs. Medtronic Stock
Investors may look for growth stocks ahead of the next bull market. 
Via The Motley Fool
3 Biotech Blockbusters to Turn $5,000 Into $50,000
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time. 
Via InvestorPlace
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
These companies are innovators, something that can prove highly lucrative. 
Via The Motley Fool
CRSP Stock Alert: What to Know as CRISPR Therapeutics Co-Founder Steps Down
With CRISPR Therapeutics announcing the departure of its co-founder, investors are also walking for the exits on CRSP stock. 
Via InvestorPlace
2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street
Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months. 
Via The Motley Fool
With a Prediction for a 70% Gain, Is Wall Street Too Optimistic About This Biotech Stock?
Big news could come in December and in March. 
Via The Motley Fool
The 3 Best Biotech Stocks to Buy Now: September 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
2 Spectacular Growth Stocks You Can Buy in September With No Hesitation
There's no need for any anxiety with investing in these great stocks. 
Via The Motley Fool
3 Beaten-Down Biotech Stocks Bound for a Bounce Back
Biotech stocks are still below their post-pandemic peaks. But these beaten-down biotech stocks could lead the sector to new highs. 
Via InvestorPlace
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
The famous growth investor has been making some interesting stock moves lately. 
Via The Motley Fool
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks deserve more respect than they're getting. 
Via The Motley Fool
Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks
The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases. 
Via The Motley Fool
3 Clever Tricks to Find Winning Biotech Stocks
You'll need to dig into company details, but the effort is worthwhile. 
Via The Motley Fool
Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M
Via Benzinga
Topics Earnings
Exposures Financial
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Helping save and improve patients' lives in novel ways can be a lucrative activity. 
Via The Motley Fool
Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead
Via Benzinga
Stocks to Watch This Week’s Top 7 Wall Street Upgrades
With the market printing some red ink recently, investors may take greater confidence in the top Wall Street upgrades this week. 
Via InvestorPlace
Gene Therapy Breakthroughs On The Horizon
Vertex Pharmaceuticals and CRISPR Therapeutics, alongside bluebird bio, are penning a new chapter in the story of gene therapy for sickle cell disease. 
Via Talk Markets
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.